CoChat

Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon

Srivastava, Gitanjali, Apovian, Caroline · 2018 · Current Obesity Reports

The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.

Abstract

Purpose of review Obesity is a global health crisis with detrimental effects on all organ systems leading to worsening disease state and rising costs of care. Persons with obesity failing lifestyle therapies need to be escalated to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery if criteria are met and more aggressive intervention is needed. The progression of severe obesity in the patient population coupled with related co-morbidities necessitates the development of novel therapies for the treatment of obesity. This development is preceded by increased understanding of the underpinnings of energy regulation and neurohormonal pathways involved in energy homeostasis. Recent findings Though there are approved anti-obesity drugs available in the USA, newer drugs are now in the pipeline for development given the urgent need. This review focuses on anti-obesity drugs in the pipeline including centrally acting agents (setmelanotide, neuropeptide Y antagonist [velneperit], zonisamide-bupropion [Empatic], cannabinoid type-1 receptor blockers), gut hormones and incretin targets (new glucagon-like-peptide-1 [GLP-1] analogues [semaglutide and oral equivalents], amylin mimetics [davalintide, dual amylin and calcitonin receptor agonists], dual action GLP-1/glucagon receptor agonists [oxyntomodulin], triple agonists [tri-agonist 1706], peptide YY, leptin analogues [combination pramlintide-metreleptin]), and other novel targets (methionine aminope…

Overview

Integrity signals

Registry

Crossref · 10.1007/s13679-018-0300-4

Cites

132 of 132 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 132 references

Research works printed but not linked: 6

  1. European Medicines Agency: European Public Assessment Report (EPAR) Acomplia. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000666/WC500021282.pdf Accessed September 27, 2017 (2007).
  2. R&D Pipeline. https://www.novonordisk.com/rnd/rd-pipeline.html Novo Nordisk Accessed August 28, 2017 (2017).
  3. Myalept [package insert]. Amylin Pharmaceuticals https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125390s000lbl.pdf Acccessed September 5, 2017 (2014).
  4. The Boston Globe: Zafgen drug halted after second patient dies. https://www.bostonglobe.com/business/2015/12/03/fda-orders-zafgen-halt-clinical-trial-for-obesity-drug/PwGxnqvLoIYpXZN59hPT6M/story.html Accessed September 27, 2017 (2015).
  5. Rhythm Pharmaceuticals, Inc Product pipeline: peptide therapeutics for rare genetic deficiencies resulting in life-threatening metabolic disorders. http://www.rhythmtx.com/pipeline/product-pipeline/ Accessed August 28, 2017 (2017).
  6. Double-blind, multi-center, randomized study to assess the efficacy and safety of velneperit (S-2367) and orlistat administered individually or combined with a reduced calorie diet (RCD) in obese subjects. https://clinicaltrials.gov/ct2/show/NCT01126970 Accessed September 13, 2017 (2011).

Cited by

See all 236

Metadata

Authors
Srivastava, G., & Apovian, C.
Affiliations
Boston University (US)
Corresponding author
Apovian, Caroline
Venue
Current Obesity Reports
Published
2018-03-05
Volume
7
Issue
2
Pages
147-161
ISSN
2162-4968 (ISSN-L)
OpenAlex
W2791667241
Cited by
232
References
132
Citations by year
2026: 8 · 2025: 17 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 57 · 2020: 34 · 2019: 30 · 2018: 14
FWCI
3.94
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Obesity Reports (publishedVersion)
  • PubMed (publishedVersion)
Funders
Shionogi
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
obesity pharmacotherapy, anti-obesity drugs, drug development pipeline, setmelanotide, GLP-1 receptor agonists, semaglutide, amylin receptor agonist, oxyntomodulin, peptide YY, lipase inhibitors, FGF21, energy homeostasis, neurohormonal pathways
MeSH terms
Obesity Management, Animals, Humans, Obesity, Morbid, Weight Loss, Drugs, Investigational, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. https://app.cochat.ai/papers/10.1007/s13679-018-0300-4
The paper
Srivastava, G., & Apovian, C. (2018). Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon. Current Obesity Reports. https://doi.org/10.1007/s13679-018-0300-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.